Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS

被引:30
|
作者
Huang, Z. [1 ]
Tomitaka, A. [1 ]
Raymond, A. [1 ]
Nair, M. [1 ]
机构
[1] Florida Int Univ, Dept Immunol, Inst NeuroImmune Pharmacol, Ctr Personalized Nanomed,Herbert Wertheim Coll Me, Miami, FL 33199 USA
基金
美国国家卫生研究院;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; CENTRAL-NERVOUS-SYSTEM; COMBINATION ANTIRETROVIRAL THERAPY; INHIBIT HIV-1 REPLICATION; POST-INTEGRATION LATENCY; IN-VIVO; INFECTED PATIENTS; VIRAL LOAD; NEUROCOGNITIVE DISORDERS;
D O I
10.1038/gt.2017.35
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) remains a major health hazard despite significant advances in prevention and treatment of HIV infection. The major reason for the persistence of HIV/AIDS is the inability of existing treatments to clear or eradicate the multiple HIV reservoirs that exist in the human body. To suppress the virus replication and rebound, HIV/AIDS patients must take life-long antiviral medications. The clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated nuclease 9 (Cas9) system is an emerging gene-editing technique with the potential to eliminate or disrupt HIV-integrated genomes or HIV-infected cells from multiple HIV reservoirs, which could result in the complete cure of HIV/AIDS. Encouraging progress has already been reported for the application of the CRISPR/Cas9 technique to HIV/AIDS treatment and prevention, both in vitro in human patient cells and in vivo in animal model experiments. In this review, we will summarize the most recent progress in the application of the CRISPR/Cas9 gene-editing technique to HIV/AIDS therapy and elimination. Future directions and trends of such applications are also discussed.
引用
收藏
页码:377 / 384
页数:8
相关论文
共 50 条
  • [1] Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS
    Z Huang
    A Tomitaka
    A Raymond
    M Nair
    Gene Therapy, 2017, 24 : 377 - 384
  • [2] Establishment of CRISPR/Cas9 stable astrocytes for gene-editing study for HIV eradication
    Huang, Z.
    Nair, M.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2017, 12 : S57 - S57
  • [3] A glance at the application of CRISPR/Cas9 gene-editing technology in cardiovascular diseases
    Roshanravan, Neda
    Tutunchi, Helda
    Najafipour, Farzad
    Dastouri, Mohammadreza
    Ghaffari, Samad
    Jebeli, Alireza
    JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH, 2022, 14 (02) : 77 - 83
  • [4] CRISPR/Cas9 gene-editing strategies in cardiovascular cells
    Vermersch, Eva
    Jouve, Charlene
    Hulot, Jean-Sebastien
    CARDIOVASCULAR RESEARCH, 2020, 116 (05) : 894 - 907
  • [5] Establishment of a CRISPR/Cas9 gene-editing system for Chrysanthemum morifolium
    Chen, Qi
    Zhang, Xin
    Jin, Ruibing
    Mao, Hongyu
    ORNAMENTAL PLANT RESEARCH, 2024, 4
  • [6] Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma
    Shijing Yu
    Ruirui Zhao
    Bingchen Zhang
    Chunmei Lai
    Linyan Li
    Jiangwen Shen
    Xiarong Tan
    Jingwei Shao
    Asian Journal of Pharmaceutical Sciences, 2023, 18 (04) : 3 - 23
  • [7] Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma
    Yu, Shijing
    Zhao, Ruirui
    Zhang, Bingchen
    Lai, Chunmei
    Li, Linyan
    Shen, Jiangwen
    Tan, Xiarong
    Shao, Jingwei
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 18 (04)
  • [8] Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment
    Jiang, Chunyang
    Meng, Lingxiang
    Yang, Bingjun
    Luo, Xin
    CLINICAL GENETICS, 2020, 97 (01) : 73 - 88
  • [9] CRISPR/CAS9 GENE EDITING
    不详
    CHEMICAL & ENGINEERING NEWS, 2015, : 26 - 27
  • [10] Prospects and challenges of CRISPR/Cas9 gene-editing technology in cancer research
    Ning, Li
    Xi, Jiahui
    Zi, Yin
    Chen, Min
    Zou, Qingjian
    Zhou, Xiaoqing
    Tang, Chengcheng
    CLINICAL GENETICS, 2023, 104 (06) : 613 - 624